Original Source(s)
Related Content
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
Urine Bladder Cancer Test Could Triage Cystoscopy
Real-world UK study suggests molecular testing could help prioritize patients with hematuria for urgent bladder investigation
September 11, 2026
-
2 min
Measles Returns as Vaccination Rates Fall
As cases increase, laboratories and public health teams must be prepared to recognize and investigate suspected infections
September 14, 2026
-
3 min